We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$30.3M
Cap. Flow %
2.77%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.49%
2 Miscellaneous 34.04%
3 Technology 6.57%
4 Consumer Discretionary 1.18%
5 Industrials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$302M 27.56%
3,335,000
+635,000
+24% +$54M
BMY icon
2
Bristol-Myers Squibb
BMY
$129B
$42M 3.83%
879,900
+249,900
+40% +$12.4M
JNJ icon
3
Johnson & Johnson
JNJ
$646B
$37M 3.38%
+265,000
New +$35.5M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$33.8M 3.09%
2,488,078
+40,084
+2% +$490K
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$33.4M 3.05%
247,300
+79,200
+47% +$9.85M
MRK icon
6
Merck
MRK
$362B
$31.4M 2.86%
395,096
-99,560
-20% -$7.45M
GILD icon
7
Gilead Sciences
GILD
$185B
$31.2M 2.85%
480,000
+130,000
+37% +$8.64M
VTRS icon
8
Viatris
VTRS
$19.7B
$28.4M 2.59%
1,002,307
-674,934
-40% -$19.7M
CELG
9
PUT
DELISTED
Celgene Corp
CELG
$28.3M 2.58%
+300,000
New +$26.2M
AZN icon
10
AstraZeneca
AZN
$257B
$28.3M 2.58%
350,000
+92,500
+36% +$7.29M
CELG
11
DELISTED
Celgene Corp
CELG
$23.6M 2.15%
250,000
-215,000
-46% -$18.8M
NVO
12
Novo Nordisk
NVO
$191B
$20.9M 1.91%
+800,000
New +$19.7M
GSK icon
13
GSK
GSK
$102B
$18M 1.64%
344,000
+96,000
+39% +$4.8M
VRNT
14
DELISTED
Verint Systems
VRNT
$15.8M 1.44%
518,087
+225,404
+77% +$5.73M
BIIB icon
15
PUT
Biogen
BIIB
$32.2B
$14.2M 1.29%
+60,000
New +$18.9M
BLUE
16
DELISTED
bluebird bio
BLUE
$13.2M 1.2%
6,469
-4,246
-40% -$7.48M
QURE icon
17
CALL
uniQure
QURE
$3.04B
$11.9M 1.09%
+200,000
New +$8.93M
URGN icon
18
UroGen Pharma
URGN
$2.12B
$11.4M 1.04%
+308,377
New +$12.9M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$11.2M 1.02%
+100,000
New +$10.9M
TVTX icon
20
Travere Therapeutics
TVTX
$6.04B
$9.86M 0.9%
435,678
+110,000
+34% +$2.43M
ALDX icon
21
Aldeyra Therapeutics
ALDX
$83.9M
$9.65M 0.88%
1,069,089
-163,000
-13% -$1.39M
NVS icon
22
Novartis
NVS
$267B
$9.61M 0.88%
+111,600
New +$8.96M
SRPT icon
23
Sarepta Therapeutics
SRPT
$2.18B
$8.75M 0.8%
73,405
-43,112
-37% -$5.54M
PTCT icon
24
PTC Therapeutics
PTCT
$5.62B
$8.3M 0.76%
220,500
-125,000
-36% -$4.2M
CLLS
25
Cellectis
CLLS
$148M
$8.22M 0.75%
447,970
– –
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management's Q1 2019 filing shows 36 new, 27 increased, 26 reduced and 32 closed positions. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M. The largest sale was Viatris, an estimated $19.7M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.